Sravan Emany

Sravan Emany

DirectoratBeam Therapeutics· In proxies 2024–2025

Pay in FY2025-73% from the year before · Beam Therapeutics stock +11.8% the same year

Sravan Emany was paid $1.3M in FY2025 (Dec), down 73%. Beam Therapeutics stock rose 11.8% that year.

Pay$100 in the stock at the end of FY23 → $102
Pay is from the Summary Compensation Table of each Beam Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Kyverna TherapeuticsPublic company · 1 yr
    • Director2025 – Present · 1 yrNo stock prices for these years
  2. Beam TherapeuticsPublic company · 2 yr
    • CFO2024 – Present · 2 yrStock in role -3%
  3. Assertio Holdings, Inc.Public company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Boards1

  • Kyverna TherapeuticsDirector · -1 yr on the boardIndependentAudit (Chair), Nominating and Corporate Governance—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?